Key result
The prevalence of polypharmacy among adults in the Netherlands increased from 3.1% in 1999 to 8.0% in 2014, a relative increase that was larger than that observed in the United States.
Why the study?
Polypharmacy is increasingly common due to an ageing population, posing problems for patients and society, but trends stratified by age and compared with the US were uncharacterized.
Cross-Sectional
Polypharmacy prevalence more than doubled in the Netherlands from 1999 to 2014, driven partly by increases in guideline-recommended preventive drugs, with a larger relative increase than in the US.
May prompt closer polypharmacy monitoring in Europe; extends US data but leaves open drivers and outcomes.
BACKGROUND AND PURPOSE: Polypharmacy is becoming increasingly common owing to the ageing population, which can pose problems for patients and society. We investigated the trends in polypharmacy and underlying drug groups among adults in the Netherlands from 1999 to 2014 stratified by age, and compared these with findings from the United States (US). METHODS: We conducted a repeated cross-sectional study using the Dutch IADB.nl prescription database. All patients aged 20 years and older in the period 1999 to 2014 were included. Polypharmacy was defined as the dispensing of five or more chronic drugs at the pharmacological subgroup level. Chi-square tests were applied to calculate the p-value for trends. Changes in prevalences were compared between the Netherlands and the US. RESULTS: The prevalence of polypharmacy increased from 3.1% to 8.0% (p-value for trend <0.001) over 15 years, and increased in all age groups. The highest rates were observed in patients aged ≥65 years, but the relative increase over time was higher in the younger age groups. Overall, large increases were observed for angiotensin-II inhibitors, statins and proton-pump inhibitors. The relative increase in polypharmacy was larger in the Netherlands than in the US (ratio of polypharmacy prevalence 2.4 versus 1.8). The Netherlands showed larger relative increases for angiotensin-II inhibitors, statins, proton-pump inhibitors, biguanides and smaller relative increases for antidepressants, benzodiazepines and insulins. CONCLUSIONS: Polypharmacy more than doubled from 1999 to 2014, and this increase was not limited to the elderly. The relative increase was larger in the Netherlands compared to the US, which was partly due to larger increases in several guideline-recommended preventive drugs.
No takes yet. Share an insight, caveat, or question.
Oktora et al. (2019) conducted a cross-sectional in Polypharmacy. Time period (1999 to 2014) vs. 1999 (baseline) was evaluated on Prevalence of polypharmacy (dispensing of five or more chronic drugs) (p=<0.001). The prevalence of polypharmacy among adults in the Netherlands increased from 3.1% in 1999 to 8.0% in 2014, a relative increase that was larger than that observed in the United States.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: